Lantern Pharma has received FDA clearance to launch a Phase Ib/II clinical trial of LP-184 for triple-negative breast cancer (TNBC). The small-molecule drug, developed using Lantern’s AI platform, targets prostaglandin reductase 1 (PTGR1) and is designed to be highly effective in tumors with DNA damage repair gene alterations.
